Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo

  • Xavier d'Anglemont de Tassigny,

    Current address: Instituto de Biomedicina de Sevilla (IBiS), Campus del Hospital Universitario Virgen del Rocio, Sevilla, Spain

    Affiliation Reproductive Physiology Group, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom

  • Channa Jayasena,

    Affiliation Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London at Hammersmith Campus, Commonwealth Building, London, United Kingdom

  • Kevin G. Murphy,

    Affiliation Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London at Hammersmith Campus, Commonwealth Building, London, United Kingdom

  • Waljit S. Dhillo,

    Affiliation Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London at Hammersmith Campus, Commonwealth Building, London, United Kingdom

  • William H. Colledge

    Affiliation Reproductive Physiology Group, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom


Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo

  • Xavier d'Anglemont de Tassigny, 
  • Channa Jayasena, 
  • Kevin G. Murphy, 
  • Waljit S. Dhillo, 
  • William H. Colledge


Kisspeptins regulate the mammalian reproductive axis by stimulating release of gonadotrophin releasing hormone (GnRH). Different length kisspeptins (KP) are found of 54, 14, 13 or 10 amino-acids which share a common C-terminal 10-amino acid sequence. KP-54 and KP-10 have been widely used to stimulate the reproductive axis but data suggest that KP-54 and KP-10 are not equally effective at eliciting reproductive hormone secretion after peripheral delivery. To confirm this, we analysed the effect of systemic administration of KP-54 or KP-10 on luteinizing hormone (LH) secretion into the bloodstream of male mice. Plasma LH measurements 10 min or 2 hours after kisspeptin injection showed that KP-54 can sustain LH release far longer than KP-10, suggesting a differential mode of action of the two peptides. To investigate the mechanism for this, we evaluated the pharmacokinetics of the two peptides in vivo and their potential to cross the blood brain barrier (BBB). We found that KP-54 has a half-life of ~32 min in the bloodstream, while KP-10 has a half-life of ~4 min. To compensate for this difference in half-life, we repeated injections of KP-10 every 10 min over 1 hr but failed to reproduce the sustained rise in LH observed after a single KP-54 injection, suggesting that the failure of KP-10 to sustain LH release may not just be related to peptide clearance. We tested the ability of peripherally administered KP-54 and KP-10 to activate c-FOS in GnRH neurons behind the blood brain barrier (BBB) and found that only KP-54 could do this. These data are consistent with KP-54 being able to cross the BBB and suggest that KP10 may be less able to do so.


Kisspeptins are a family of neuropeptides encoded by the Kiss1 gene that are critical for activation of the mammalian reproductive axis at puberty [1] and regulation of ovulation in sexually mature females [2]. In humans, they are generated from a 145-amino acid precursor to produce smaller amidated peptides of 54, 14, 13 or 10-amino acids that all share the common C-terminal decapeptide sequence. Kisspeptins act via the G-protein coupled receptor, KISS1R (also known as GPR54) to stimulate GnRH release and subsequent secretion of gonadotrophic hormones (LH and FSH) in all mammalian species examined [38]. Inactivating mutations in KISS1R or KISS1 cause hypogonadotrophic hypogonadism in humans and mice [1, 911].

The potency of the different kisspeptins has been examined both in vitro and in vivo. In general, all forms of kisspeptin show similar receptor binding affinities and cell signalling properties in vitro [12]. KP-10 exerts a potent direct depolarizing action on GnRH neurons and increases their firing rate in acute brain slices [13]. Moreover, KP-54 and KP-10 induce robust LH release after direct delivery into the brain with similar effects [3]. In contrast, KP-54 and KP-10 have different potencies when they are delivered systemically. This is particularly relevant for the proposed clinical use of kisspeptins, as they will most likely be administered peripherally rather than directly into the brain. Peripheral delivery of KP-54 stimulated release of LH over a sustained period of 1 to 4 hours, while KP-10 induced less sustained LH secretion between 10 min to 1 h [5, 1418]. The reason for this difference in the potency of KP-54 and KP-10 after systemic delivery is not known. It may be caused by differences in the half-life of each peptide in the blood stream or by differences in their ability to cross the blood-brain barrier. We have directly compared KP-54 and KP-10 to gain an insight into why KP-54 elicits more sustained responses than KP-10 after systemic delivery. This knowledge will be relevant when considering which form of kisspeptin to use in a clinical setting and in understanding the mechanisms of action of the different kisspeptins.

Materials and methods

Study 1: Effect of peripheral administration of KP-54 or KP-10 on plasma LH levels in male mice

Male mice received a single intraperitoneal (i.p.) injection of 100 μl of PBS (vehicle control; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8mM KH2PO4, pH 7.4), KP-10 (1 nmol), or KP-54 (1 nmol) in PBS and LH levels in the plasma measured at 10 min and 2 h after treatment to compare early and late responses points. We chose the 10 min point as some studies have shown that KP-10 injection results in maximal LH secretion after 10–15 min [16, 18]. 100 μl of blood was collected from a tail vein 10 min after injection, mixed with 5 μl EDTA and centrifuged at 10,000 x g for 10 min at 4°C. The plasma supernatant was stored at -20°C until assayed. Two hours after injection, mice were deeply anaesthetized with pentobarbital (100mg/kg i.p.), ~300 μl of blood was rapidly collected from the vena cava and processed as described above. Finally the mice were perfused intracardially with 20 ml of 4% paraformaldehyde in PBS. Brains were removed and incubated for 1 h in the same fixative as for perfusion and placed in PBS for sectioning and immunohistochemistry processing.

Study 2: Effect of peripheral administration of a high dose or multiple injections of KP-10 on plasma LH levels in male mice

Male mice received a single intraperitoneal (i.p.) injection of 100 μl of PBS (vehicle control), KP-10 (1 nmol), KP-10 (10 nmol), KP-54 (1 nmol) or a series of six i.p. injections (every 10 minutes over one hour) of KP-10 (1 nmol) to extend the duration of action of KP-10. 100 μl of blood was collected from a tail vein 10 min after the final injection and the mice were killed 2 hours after treatment by an injection of pentobarbital (100mg/kg i.p.). Blood was collected from the vena cava, mixed with 5 μl EDTA, centrifuged at 10,000 x g for 10 min at 4°C to obtain the plasma fraction, and stored at -20°C until assayed.

Study 3: Effect of peripheral administration of KP-54 or KP-10 on c-FOS neuronal activation in the hypothalamus

The aim of this study was:

  1. To determine areas in the hypothalamus in which peripheral administration of KP-54 or KP-10 activates c-FOS in GnRH neurons
  2. To determine if peripheral administration of KP-54 or KP-10 activates c-FOS in GnRH neurons in areas of the hypothalamus that are behind the blood brain barrier.

Induction of expression of the immediate early gene c-Fos is regarded as a marker of neuronal activation [19]. KISS1R activation results in c-FOS induction, which allows identification of the GnRH neurons that are activated by KP. We examined co-localization of c-FOS protein in GnRH neurons by immunohistochemistry 2h after peripheral injection of either KP-10 or KP-54. To define hypothalamic neurons behind the blood-brain-barrier (BBB), some mice were injected with bovine serum albumin conjugated with fluorescein isothiocyanate (BSA-FITC), a compound that can be used to detect microvascular leakage and does not cross the BBB [20]. 1 nmol KP-54 was injected first, followed by injection of 100 μl of a 50mg/ml solution of BSA-FITC into the tail vein. The mice were perfused with 4% paraformaldehyde/PBS 2 hrs after KP-54 injection and the brains processed for c-FOS, GnRH and BSA-FITC detection. A negative control for fluorescence was also performed with unconjugated BSA.

Study 4: To determine the pharmacokinetics of plasma kisspeptin levels following peripheral KP-54 or KP-10 administration in male mice

Male mice received a single i.p. injection of 1 nmol KP-10 or 1 nmol KP-54. 100 μl of blood was collected from the lateral tail vein from groups of mice (n = 4) for each time point (0, 1 min, 2 min, 5 min, 10 min, 30 min, 60 min and 120 min). Terminal bleeds were collected from the vena cava. Blood was mixed with 5 μl EDTA, centrifuged at 10,000 x g for 10 min at 4°C to obtain the plasma fraction, and stored at -20°C until assayed. Kisspeptin concentrations were measured using an established in house competitive radioimmunoassay (RIA, [5]. Briefly, this RIA uses a sheep polyclonal antibody (GQ2), raised against human KP-54, which cross-reacts with human KP-54, KP-14 and KP-10.


3–5 month old wild-type (129S6/SvEv) male mice were used in this study. The mice were housed in open cages on a 12 hour light cycle (lights on at 0700 h) at a controlled temperature (22°C), and were provided with food and water ad libitum. All experiments were performed under the authority of a United Kingdom Home Office Project License and were approved by a Cambridge Animal Ethics Committee.


KP-10 [human Metastin (45–54) amide, M-2816] was purchased from Sigma-Aldrich. KP-10 consists of the C-terminal 10-amino acids of KP-54. Human KP-54 was synthesized by the Advanced Biotechnology Centre, Imperial College, London, UK. BSA-FITC was purchased from Sigma (A9771). From the product data sheets, the solubility of KP-10 and KP-54 in water is 1mg/ml. We prepared stock solutions in sterile PBS at 100 μM, which is almost ten times lower than the solubility limit set by the manufacturer. The 100 μM stock solution was diluted in sterile PBS and 100 μl of the working solution was injected to each mouse. PBS was used for vehicle control injections.

The rabbit anti-GnRH antibody was a gift from Dr. Vincent Prévot (Institut National de la Santé et de la Recherche Médicale U837, University of Lille 2, Lille, France). The rabbit polyclonal anti c-FOS antibody (SC-52) was purchased from Santa Cruz Biotechnology and previously used on mouse tissue [21]. Secondary goat anti-rabbit biotin-conjugated (BA-1000), anti-rabbit peroxidase-conjugated (PI-1000), and Vectastain ABC kit (PK-4000) were purchased from Vector Laboratories.


Free-floating, dual-label chromogen immunohistochemistry was undertaken as described previously [2, 21]. Mice were perfused with 4% paraformaldehyde in PBS and the brains removed and post-fixed for 1h in the same fixative. The brains were cut as 40 μm free-floating coronal sections using a vibratome (VT1000S; Leica). Sections containing GnRH neurons were taken from the region of the medial septum through to the caudal hypothalamus. Sections were treated with 3% hydrogen peroxide for 10 min to quench endogenous peroxidase activity and then washed in Tris buffered saline (TBS) (0.5 M Tris, pH 7.6 and 0.15 M sodium chloride). For the first immunolabelling, sections were incubated for 16 h at 4°C with a primary rabbit polyclonal anti-sera directed against c-FOS (sc-52, Santa Cruz Biotechnology, USA) at 1:1000 in TBS containing 0.3% Triton X-100 (TBS-T) and 5% normal goat serum (blocking solution). Sections were then incubated with biotinylated anti-rabbit IgG (Vector Laboratories, USA) at 1:500 in blocking solution for 1 h at room temperature. After subsequent washing in TBS, the sections were incubated in Vectastain ABC avidin–peroxidase (Vector Laboratories, USA) at 1:100 in TBS-T for 1 h at room temperature. Immunoreactivity was revealed using glucose–oxidase, nickel-enhanced diaminobenzidine hydrochloride (DAB) that resulted in a black precipitate within the nucleus of the labelled cell. For the second immunolabelling, sections were washed in 3% hydrogen peroxide to quench any remaining peroxidase, washed in TBS, and then incubated with polyclonal rabbit anti-GnRH antibody (1:3000) in blocking solution for 16 h at 4°C. The rabbit anti-GnRH antibody was a gift from Dr. Vincent Prévot (University of Lille, France) initially generated and validated by Professor Gerard Tramu [22]. Sections were then incubated in peroxidase-conjugated anti-rabbit IgG (Vector Laboratories, USA) (1:500) in blocking solution for 1 h at room temperature. Immunoreactivity was revealed using glucose oxidase and DAB without nickel to generate a brown precipitate within the cytoplasm. Brain sections were mounted on slides, dehydrated, and cover slipped with DPX (44581; Sigma-Aldrich).

Immunohistochemistry analysis

Sections were examined using an Axioscope 2 plus microscope (Carl Zeiss) using bright-field or fluorescence microscopy. Analysis of the double-labelled tissue was undertaken by counting the number of single-labelled (brown cytoplasm only) and dual-labelled (brown cytoplasm and black nucleus) neurons. The examiner was blinded of the treatment at the time of counting. Where appropriate, BSA-FITC was detected by epifluorescence microscopy at an excitation wavelength of 490 nm and an emission wavelength of 525 nm (green). About fifteen successive sections containing GnRH neurons were counted per animal (n = 6 per treatment). GnRH neuron subpopulations were separated into four hypothalamic regions [23]: the medial septum plus the diagonal band nucleus (MS/NDB), the medial preoptic area and ventromedial preoptic nucleus (MPO/VMPO), the vascular organ of the lamina terminalis (OVLT), and the median preoptic nucleus (MEPO) according to the Allen Mouse Brain Atlas.

Luteinizing hormone ELISA

Plasma LH was assayed using a commercial ELISA kit (LH Ultrasensitive Rodent ELISA, Endocrine Technologies Cat Number ERK 7010+) with a sensitivity of 0.3 ng/ml and 7% intra-assay and 10% inter-assay coefficients of variation. 50 μl plasma samples from the vena cava were assayed in duplicate, but samples from tail vein bleeds were assayed with one replicate owing to limited sample volume.


Differences between groups were analyzed by one-way ANOVA assuming a Gaussian distribution, followed with Tukey multiple comparison test for unequal replication. The comparison between two groups was analysed by an unpaired, two-tailed, Student’s t-test. A P-value of less than 0.05 was taken as significant.


Peripheral administration of KP-54 or KP-10 has different effects on LH secretion in male mice

The aim of these experiments was to compare the effect of KP-54 or KP-10 on LH secretion in vivo.

Study 1.

In the first experiment, we assessed LH secretion after of a single intraperitoneal injection of KP-54 or KP-10 at the commonly used dose of 1 nmol (Fig 1A). In wild-type male mice, KP-54 increased plasma LH levels above vehicle control at 10 min (5.70 ± 0.69 ng/ml, p < 0.001) and at 2 hours (6.42 ± 1.74 ng/ml, p < 0.01) post-injection. KP-10 significantly increased LH levels at 10 min (3.22 ± 0.86 ng/ml, p < 0.01 vs. PBS treatment 0.06 ± 0.04 ng/ml), but to a significantly lower level than KP-54 at the same time point (p = 0.05). Two hours after KP-10 injection however, LH had returned to basal levels (0.25 ± 0.11 ng/ml, p < 0.01 vs KP-54 at 2 hrs and p < 0.01 vs KP-10 at 10 min).

Fig 1. Peripheral administration of KP-54 stimulates plasma LH levels in male mice more potently than KP-10.

(A) Bar graph showing the mean ± s.e.m. of LH levels in adult male mice 10 min and 2 hrs after intraperitoneal injection of PBS (veh, n = 8), 1 nmol KP-10 (n = 8), or 1 nmol KP-54 (n = 8). (B) Bar graph showing the mean ± s.e.m. of plasma LH levels 10 min and 2 hrs after intraperitoneal injection of PBS (n = 4), 1 nmol KP-10 (n = 5), 10 nmol (n = 4), 6 repeats of 1 nmol KP-10 every 10 min for 1h (n = 4), or 1 nmol KP-54 (n = 10). Letters indicate differences between groups at the p<0.05 significance level with higher P-values indicated (One-way ANOVA, followed by Tukey’s multiple comparison test was used to compare treatment groups).

Study 2.

We performed a second series of experiments to test the effects of a 10-fold higher dose (10 nmol) or multiple injections of KP-10 (1nmol) on LH secretion (Fig 1B). A single injection of 10 nmol KP-10 resulted in a significantly greater increase in LH after 10 min (6.39 ± 0.37 ng/ml) than a single injection of 1 nmol KP-10 (4.62 ± 0.29 ng/ml, p < 0.01), but LH had returned to basal levels (0.31 ± 0.12 ng/ml) by 2 hrs. Similarly, six-repeated injections (every 10 minutes for 1h) of 1 nmol KP-10 failed to sustain LH at the 2 h time point (0.54 ± 0.14, ng/ml). In the same experiment, a single i.p. injection of 1 nmol KP-54 induced a robust and sustained LH release at 2 hrs (9.62 ± 1.67 ng/ml). We attempted to facilitate greater permeability of KP-10 across the blood brain barrier (BBB) by adding a penetratin sequence [24] to the C-terminal end of the decapeptide but this did not further increase plasma LH levels (S1 Fig).

Peripheral KP-54 (but not KP-10) induces c-FOS in GnRH neurons located behind the blood brain barrier

Study 3.

To further explore the mechanistic differences between KP-10 and KP-54 in the stimulation of LH release, we assessed the induction of c-FOS in GnRH neurons throughout the hypothalamic preoptic region (Fig 2A). The percentage of GnRH cells with c-FOS immunoreactivity was calculated in the four main regions of the hypothalamus that contain GnRH cells: the medial septum and diagonal band nucleus (MS/NDB), the medial preoptic area and ventromedial preoptic nucleus (MPO/VMPO), the organum vasculosum of lamina terminalis (OVLT), and the median preoptic nucleus (MEPO) (Fig 2B), We found that the percentage of GnRH neurons that were positive for c-FOS was low after peripheral KP-10 injection (0.66 ± 0.19%) and similar to the percentage activated in vehicle-treated animals (0.54 ± 0.15%) (Fig 2C). However, KP-54 induced expression of c-FOS in 22.07 ± 2.96 of the GnRH neurons (Fig 2C). The percentage of dual-labelled cells varied depending on the hypothalamic region: 4.00 ± 1.38 in the MS/NDB, 43.34 ± 4.22 in the MPO/VMPO, 82.05 ± 16.46 in the OVLT, and 21.07 ± 7.26 in the MEPO (Fig 2C). In KP-54-treated mice that also received an intravenous injection of BSA-FITC, the resulting fluorescence was restricted to the OVLT and the median eminence (ME) hypothalamic regions (Fig 3). We observed c-FOS-positive GnRH neurons in hypothalamic areas that were negative for BSA-FITC such as the MPO.

Fig 2. Peripheral administration of KP-54 but not KP-10 induces c-FOS in GnRH neurons.

(A) Representative photomicrographs showing coronal sections of dual-labelled immunohistochemistry showing c-FOS staining (black nuclei) and GnRH neurons (brown cells) at the level of the OVLT and MPO regions in the mouse hypothalamus 2 hrs after peripheral injection of KP-54 (n = 6) or KP-10 (n = 6). GnRH neurons with c-FOS staining are indicated with black arrows. Grey arrowheads indicate c-FOS negative GnRH neurons. KP-54 (but not KP-10) stimulates c-FOS in the hypothalamus (and this co-localises with GnRH neurons). Scale bar = 20 μm. (B) Schematic diagrams showing distribution of c-FOS positive (closed circles) and c-FOS negative (open circles) GnRH neurons throughout the anterior hypothalamus following peripheral administration of KP-54 (n = 6). Diagrams are re-drawn from those available from the Allen Institute for Brain Science ( ac anterior commissure; MEPO, median preoptic nucleus; MPN, medial preoptic nucleus; MPO, medial preoptic nucleus; MS, medial septum; NDB, diagonal band nucleus; oc, optic chiasm; OVLT, organum vasculosum of lamina terminalis; VMPO, ventromedial preoptic nucleus. (C) Histogram showing the number of GnRH neurons expressing c-FOS 2 hrs after PBS (veh, n = 6), KP-54 (n = 6) or KP-10 (n = 6) in different hypothalamic regions. MS/NDB, medial septum and diagonal band nucleus; MPO/VMPO, medial preoptic area and ventromedial preoptic nucleus; OVLT, organum vasculosum of lamina terminalis; MEPO, median preoptic nucleus. Significant differences between KP-54 and vehicle or KP-10 are indicated (one-way ANOVA, followed by Tukey’s multiple comparison test).

Fig 3. Peripheral administration of KP-54 activates GnRH neurons inside the blood-brain-barrier in male mice.

KP-54 (1nmol) was injected into male mice (n = 3) and activation of c-FOS in GnRH neurons determined after 2 h (A) Dual-label immunohistochemistry showing GnRH neurons (brown cytoplasmic staining) and c-FOS staining (black nuclei) in the OVLT/MPO region. Low-power view (upper panels) and higher magnified views (lower panels) of the dotted line boxes show c-FOS + GnRH neurons (arrows) in the OVLT and MPO hypothalamic regions. The c-FOS + GnRH neuron in the MPO (arrow in the centre of the picture) is clearly located inside the blood brain barrier defined by BSA-FITC staining. Scale bars: 100 μm (upper panels) and 50 μm (lower panels). (B) GnRH axon projections (brown) overlap with the BSA-FITC staining in the median eminence (EM) as this region is devoid of a blood-brain-barrier. Scale bar = 100 μm. 3V: third ventricle, OVLT: organum vasculosum of lamina terminalis, MPO: medial preoptic area.

Peripheral administration of KP-54 results in a higher peak level and longer duration of plasma kisspeptin levels compared to KP-10 in male mice

Study 4.

To further explore the difference in the potencies of KP-10 and KP-54 on stimulating LH release, we measured the rate of loss of each peptide from the bloodstream following i.p. injection. KP-10 peaked at 248 ± 9 pmol/l at 2 min post-injection and was undetectable by 10 min (Fig 4). We estimate that KP-10 has a plasma half-life of about 4 min in the mouse. In contrast, plasma KP-54 increased rapidly after injection and reached a maximum at 5 min (12292 ± 2655 pmol/l) that lasted until 30 min (13193 ± 4364 pmol/L). Thereafter, plasma KP-54 level progressively diminished to 5034 ± 787 pmol/l at 60 min and 1186 ± 330 pmol/l at 120 min post-injection. We calculated the half-life of plasma KP-54 to be around 32 min in the mouse although as the RIA can recognise all forms of Kp, this may also reflect the immunoreactivity of shorter peptides produced by the breakdown of KP-54.

Fig 4. Peripheral administration of KP-54 results in a higher peak level and longer duration of plasma kisspeptin levels compared to KP-10 in male mice.

Radioimmunoassay analysis of kisspeptin plasma levels over 2 hours after 1 nmole i.p. injection of KP-10 (n = 4) or KP-54 (n = 4). Note the different scale between the KP-10 and the KP-54 plots. Data points are means ± SEM.


Kisspeptin neuropeptides are potent stimulators of GnRH release and are being evaluated for treatment of specific human reproductive disorders [25]. These clinical studies have used peripheral delivery of either the 54 amino-acid version of kisspeptin (KP-54)[5, 2629] or the 10 amino-acid version (KP-10) [7, 8, 30]. Although KP-54 and KP-10 show similar receptor binding affinities and bioactivities in vitro, a direct comparison of their potencies in vivo is limited as most studies usually evaluate only one kisspeptin type. One study that compared KP-54 and KP-10 directly showed that injection into the brain produced similar levels of LH secretion in adult male mice after 30 mins [3]. Similarly in healthy men, continuous intravenous infusion of equimolar amounts of KP-10 or KP-54 over a 3h period also produced similar LH secretory responses [31]. Other data however, suggest that KP-54 and KP-10 have different potencies when they are delivered systemically as a single injection [1517], which is the most likely route of administration in a clinical setting. In addition, whether KP-54 and KP-10 have different mechanisms of action after systemic delivery has not been studied.

In this study, we have examined the effect of a single injection of equimolar amounts of KP-54 or KP-10 on LH secretion and c-FOS activation of GnRH neurons in mice. We find that KP-10 is less potent than KP-54 at eliciting sustained LH release and our data suggest that this is caused by a combination of factors; the ability of KP-54, but not KP-10, to cross the blood brain barrier and a better pharmacokinetic profile for KP-54 compared to KP-10 in the bloodstream. It should be noted however that we used human KP-54 and KP-10 for these studies because the RIA does not detect mouse kisspeptins. We do not know if murine kisspeptins will behave differently.

Our data suggest that KP-10 may not cross the BBB. However, it is difficult to determine whether the lack of GnRH neuronal activation following peripheral administration reflects a lack of brain access, the low circulating half-life of KP-10 or a combination of both. One caveat to our study is that the method of determining the BBB permeability is based on the functional assay of c-FOS immunoreactivity rather than direct protein measurement. To determine the relative permeability of the BBB to KP-10 vs KP-54, it would be necessary to label each peptide and quantify entry into the brain. Direct measurement of kisspeptin entry into the brain, however, is not without its difficulties. For example, any label attached to the kisspeptin protein could alter its transport properties across the BBB. Radio-labelling of kisspeptins provides a sensitive detection method but radioisotopes in the brain could be derived from peptide degradation and not necessarily represent full-length kisspeptin. To overcome these technical challenges, we decided to use c-FOS activation in those GnRH neurons, which lie behind the BBB as a functional surrogate for entry of kisspeptins into the brain.

Our data show that the stability of KP-10 in the blood stream is short with a half-life of around 4 minutes, which is very similar to the 3.8 minutes found in men [5, 30]. In contrast, KP-54 had a half-life of 32 minutes in mice, which is close to the 28 minutes found in humans [5]. It should be noted, however that the RIA used to measure KP-54 may also detect shorter breakdown products of this protein that might be biologically inert. It is likely that the lack of GnRH neuronal activation and sustained LH release by KP-10 is mainly due to its instability. It is noteworthy that we failed to find c-FOS activation in GnRH neurons located close to the OVLT, which should be accessible to KP-10 from the bloodstream suggesting that KP-10 instability may be the biggest factor for its shorter potency in vivo. To try to overcome this limitation, we injected KP-10 every 10 minutes over a 1h period (6 injections in total), to extend the duration of the actions of KP-10. This did not extend the duration of LH secretion however, which supports the suggestion that KP-10 may not be able to cross the BBB, although more frequent or continuous delivery of KP-10 might be more efficacious. In contrast, KP-54, which produced sustained LH secretion over a 2h time period, activated GnRH neurons located behind the blood brain barrier in the medial preoptic area and median preoptic nucleus. This shows that KP-54 is capable of crossing the BBB and is consistent with other studies involving peripheral delivery of KP-54 which can induce c-FOS in GnRH neurons [14]. Indeed, the finding that intravenous KP-54 injection can enhance limbic brain activity in humans is also consistent with KP-54 crossing the BBB [32]. It should be noted that c-FOS activation in GnRH neurons located within 100 μm of the OVLT region cannot be used to define the BBB, since GnRH neurons in this location extend their dendrites outside the BBB [33].

Our data also show that intraperitoneal injections of kisspeptins can rapidly access the bloodstream with KP-10 achieving maximum levels after 2 minutes and KP-54 after 5 minutes (Fig 4). Interestingly, the peak level of KP-10 in the bloodstream (250 pmol/L) is almost 50-times lower than that of KP-54 (12000pmol/L) even though equimolar amounts (1 nmole) of each peptide were injected. Thus, it is possible that 250 pmol/L of KP-10 is below a critical threshold for c-FOS induction and it might be that a much higher dose is required.

If we assume that the total blood volume for a mouse is approximately 5ml, then only around 0.13% of KP-10 and 6% of KP-54 enter the bloodstream after intraperitoneal injection. It is possible that direct injection of kisspeptins into the bloodstream, which would achieve higher circulating levels might alter the responses we have observed. If we assume that KP-54 and KP-10 are equally competent to enter the bloodstream from the peritoneal space, then the 50-fold difference in peak levels between the two peptides might indicate that KP-10 is sequestered in some way, perhaps by rapid removal from the vascular space. It is also possible that the apparent short-half life of KP-10 may reflect sequestration by serum proteins, which would reduce the availability of the peptide for measurement by the RIA

The mechanism by which KP-54 might cross the BBB is not known. Substances cross the BBB by a variety of routes including via specific transporters and transmembrane diffusion. A BLAST protein search using the KP-54 amino-acid sequence did not identify any motifs that might bind to known BBB transporter proteins. The KP-54 protein also has no predicted glycosylation sites that might allow specific transport. The KP-54 protein also has good solubility in water making it unlikely that it will cross the BBB by transmembrane diffusion, which is usually restricted to hydrophobic proteins. Interestingly, KP-10 is very hydrophobic with 5/10 amino acids being aromatic or aliphatic, which would facilitate diffusion across the BBB, but this hydrophobicity might also cause sequestration by serum proteins and limit access to the brain.

The ability of KP-10 to cross the BBB is an important question as several KP-10 analogues have been developed to act as GPR54 agonists for manipulation of the reproductive axis and to treat clinical conditions including prostate cancer [3442]. One of these KP-10 analogues (C6) has been shown to induce synchronized ovulations and allow pregnancies after a single intramuscular injection in sheep [36]. Interestingly, the LH responses with this KP-10-C6 analogue lasted up to 12 h, far longer than following systemic delivery of KP-54. It is likely that increased stability of the KP-10-C6 peptide accounts for this but whether the peptide can cross the BBB has not been studied. The C6 peptide contains an albumin-binding motif, which would reduce peptide clearance from the blood but may also limit access to the brain.

Our data indicate that peripheral injection of KP-10 can stimulate LH secretion but this is not sustained. We have shown previously using tissue explants that KP-10 can stimulate GnRH release from nerve terminals in the median eminence without the need for GnRH cell bodies [43]. In addition, immunoelectron microscopy has shown that kisspeptin nerve fibres make contact with GnRH nerve terminals in the median eminence [44] As we do not find c-FOS activation in GnRH cell bodies after KP-10 injection, this suggests that KP-10 may only be able to stimulate GnRH nerve terminals [3542] leading to a rapid and transient stimulation of gonadotrophs in the anterior pituitary, thus resulting in a short stimulation of LH release. In contrast, systemic administration of KP-54 produces a robust and sustained LH secretion by acting directly at the GnRH neuron cell body, beyond the blood-brain-barrier.

Our data are relevant to the design of kisspeptin-based treatments for infertility problems such as hypothalamic amenorrhea [28, 29] or as safer alternatives for triggers of oocyte maturation for in vitro fertilization clinical protocols [27, 45]. KP-54 and KP-10 have been used clinically to stimulate the reproductive axis of men and women and they both show physiological effects. Our data suggest, however, that KP-54 might be more efficacious than Kp-10, particularly if using a regimen involving a single injection of peptide.

Supporting information

S1 Fig. Kisspeptin-penetratin treatment.

This experiment aimed at facilitating Kp10 to cross the blood-brain-barrier by adding a penetratin extension [24] to the C-terminal end of Kp10, thereby putatively provided with higher permeability. Two penetratin variants were tested: the pen(ala2) residue has a lower protein transduction domain activity than pen-Kp10. The Kp10 peptide sequence used was Y N W N S F G L R F–NH2. The peptide sequences of modified Kp10 were: N R R M K W K K Y Y N W N S F G L R F–NH2 (Pen-Kp10), and N R R M A W A K Y Y N W N S F G L R F–NH2 (Pen(ala2)-Kp10). Each animal received a single 100 μl i.p. injection of either PBS, Kp10, Kp54, Pen-Kp10 or Pen(ala2)-Kp10. Blood samples were collected at 10 min (from tail vein) and 2 hrs (from vena cava upon sacrifice) time points after administration. The results from two animals per treatment (n = 2), suggest that adding a penetratin residue to the Kp10 decapeptide does not improve the Kp10-induced LH secretion.



We would like to thank all the staff in the Biofacility for their excellent husbandry. We are also indebted to Massimiliano Beltramo for comments on the manuscript.

Author Contributions

  1. Conceptualization: XdAT WHC.
  2. Formal analysis: XdAT WHC.
  3. Funding acquisition: WHC.
  4. Investigation: XdAT CJ KGM WSD WHC.
  5. Methodology: XdAT WHC.
  6. Project administration: WHC.
  7. Resources: CJ KGM WSD.
  8. Supervision: WHC WSD.
  9. Validation: XdAT.
  10. Visualization: XdAT.
  11. Writing – original draft: XdAT WHC.
  12. Writing – review & editing: XdAT CJ KGM WSD WHC.


  1. 1. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614–27. pmid:14573733
  2. 2. Clarkson J, d'Anglemont de Tassigny X, Moreno AS, Colledge WH, Herbison AE. Kisspeptin-GPR54 signaling is essential for preovulatory gonadotropin-releasing hormone neuron activation and the luteinizing hormone surge. J Neurosci. 2008;28(35):8691–7. Epub 2008/08/30. pmid:18753370
  3. 3. Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV, Crowley WF, et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology. 2004;145(9):4073–7. pmid:15217982
  4. 4. Thompson EL, Patterson M, Murphy KG, Smith KL, Dhillo WS, Todd JF, et al. Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol. 2004;16(10):850–8. pmid:15500545
  5. 5. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609–15. pmid:16174713
  6. 6. Messager S, Chatzidaki EE, Ma D, Hendrick AG, Zahn D, Dixon J, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci U S A. 2005;102(5):1761–6. pmid:15665093
  7. 7. George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. J Clin Endocrinol Metab. 2011;96(8):E1228–36. Epub 2011/06/03. pmid:21632807
  8. 8. George JT, Anderson RA, Millar RP. Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback. Hum Reprod. 2012;27(12):3552–9. pmid:22956346
  9. 9. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972–6. pmid:12944565
  10. 10. Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, Erdogan S, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366(7):629–35. Epub 2012/02/18. pmid:22335740
  11. 11. d'Anglemont de Tassigny X, Fagg LA, Dixon JP, Day K, Leitch HG, Hendrick AG, et al. Hypogonadotropic hypogonadism in mice lacking a functional Kiss1 gene. Proc Natl Acad Sci U S A. 2007;104(25):10714–9. pmid:17563351
  12. 12. Kotani M, Mollereau C, Detheux M, Le Poul E, Brezillon S, Vakili J, et al. Functional characterization of a human receptor for neuropeptide FF and related peptides. Br J Pharmacol. 2001;133(1):138–44. Epub 2001/04/28. pmid:11325803
  13. 13. Han SK, Gottsch ML, Lee KJ, Popa SM, Smith JT, Jakawich SK, et al. Activation of gonadotropin-releasing hormone neurons by kisspeptin as a neuroendocrine switch for the onset of puberty. J Neurosci. 2005;25(49):11349–56. pmid:16339030
  14. 14. Matsui H, Takatsu Y, Kumano S, Matsumoto H, Ohtaki T. Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochem Biophys Res Commun. 2004;320(2):383–8. pmid:15219839
  15. 15. Pheng V, Uenoyama Y, Homma T, Inamoto Y, Takase K, Yoshizawa-Kumagaye K, et al. Potencies of centrally- or peripherally-injected full-length kisspeptin or its C-terminal decapeptide on LH release in intact male rats. J Reprod Dev. 2009;55(4):378–82. pmid:19384054
  16. 16. Navarro VM, Castellano JM, Fernandez-Fernandez R, Tovar S, Roa J, Mayen A, et al. Characterization of the potent luteinizing hormone-releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology. 2005;146(1):156–63. pmid:15375028
  17. 17. Thompson EL, Murphy KG, Patterson M, Bewick GA, Stamp GW, Curtis AE, et al. Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats. Am J Physiol Endocrinol Metab. 2006;291(5):E1074–82. pmid:16787965
  18. 18. Albers-Wolthers KH, de Gier J, Kooistra HS, Rutten VP, van Kooten PJ, de Graaf JJ, et al. Identification of a novel kisspeptin with high gonadotrophin stimulatory activity in the dog. Neuroendocrinology. 2014;99(3–4):178–89. pmid:24902774
  19. 19. Morgan JI, Cohen DR, Hempstead JL, Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science. 1987;237(4811):192–7. pmid:3037702
  20. 20. Lominadze D, Roberts AM, Tyagi N, Moshal KS, Tyagi SC. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol. 2006;290(3):H1206–13. pmid:16258031
  21. 21. d'Anglemont de Tassigny X, Ackroyd KJ, Chatzidaki EE, Colledge WH. Kisspeptin signaling is required for peripheral but not central stimulation of gonadotropin-releasing hormone neurons by NMDA. J Neurosci. 2010;30(25):8581–90. pmid:20573904
  22. 22. Beauvillain JC, Tramu G. Immunocytochemical demonstration of LH-RH, somatostatin, and ACTH-like peptide in osmium-postfixed, resin-embedded median eminence. J Histochem Cytochem. 1980;28(9):1014–7. pmid:6157712
  23. 23. Herbison AE, de Tassigny X, Doran J, Colledge WH. Distribution and postnatal development of Gpr54 gene expression in mouse brain and gonadotropin-releasing hormone neurons. Endocrinology. 2010;151(1):312–21. pmid:19966188
  24. 24. Fischer PM, Zhelev NZ, Wang S, Melville JE, Fahraeus R, Lane DP. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J Pept Res. 2000;55(2):163–72. pmid:10784032
  25. 25. Prague JK, Dhillo WS. Potential Clinical Use of Kisspeptin. Neuroendocrinology. 2015;102(3):238–45. pmid:26277870
  26. 26. Dhillo WS, Chaudhri OB, Thompson EL, Murphy KG, Patterson M, Ramachandran R, et al. Kisspeptin-54 Stimulates Gonadotrophin Release Most Potently During The Preovulatory Phase Of The Menstrual Cycle In Women. J Clin Endocrinol Metab. 2007.
  27. 27. Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667–77. pmid:25036713
  28. 28. Jayasena CN, Nijher GM, Abbara A, Murphy KG, Lim A, Patel D, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010;88(6):840–7. Epub 2010/10/29. pmid:20980998
  29. 29. Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315–23. pmid:19820030
  30. 30. Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewki A, Vaal ML, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(12):E1963–72. Epub 2011/10/07. pmid:21976724
  31. 31. Jayasena CN, Abbara A, Narayanaswamy S, Comninos AN, Ratnasabapathy R, Bassett P, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction. 2015;30(8):1934–41. pmid:26089302
  32. 32. Comninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Narayanaswamy S, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709–19. pmid:28112678
  33. 33. Herde MK, Geist K, Campbell RE, Herbison AE. Gonadotropin-releasing hormone neurons extend complex highly branched dendritic trees outside the blood-brain barrier. Endocrinology. 2011;152(10):3832–41. Epub 2011/07/28. pmid:21791557
  34. 34. Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013;9(8):451–66. pmid:23817290
  35. 35. Curtis AE, Cooke JH, Baxter JE, Parkinson JRC, Bataveljic A, Ghatei MA, et al. A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10. Am J Physiol-Endoc M. 2010;298(2):E296–E303.
  36. 36. Decourt C, Robert V, Anger K, Galibert M, Madinier JB, Liu X, et al. A synthetic kisspeptin analog that triggers ovulation and advances puberty. Sci Rep. 2016;6:26908. pmid:27245315
  37. 37. Endo N, Tamesaki C, Ohkura S, Wakabayashi Y, Matsui H, Tanaka A, et al. Differential changes in luteinizing hormone secretion after administration of the investigational metastin/kisspeptin analog TAK-683 in goats. Anim Reprod Sci. 2015;159:87–93. pmid:26051610
  38. 38. Goto Y, Endo N, Nagai K, Ohkura S, Wakabayashi Y, Tanaka A, et al. Ovarian and hormonal responses to follicular phase administration of investigational metastin/kisspeptin analog, TAK-683, in goats. Reprod Domest Anim. 2014;49(2):338–42. pmid:24484509
  39. 39. MacLean DB, Matsui H, Suri A, Neuwirth R, Colombel M. Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies. J Clin Endocrinol Metab. 2014;99(8):E1445–53. pmid:24762108
  40. 40. Matsui H, Tanaka A, Yokoyama K, Takatsu Y, Ishikawa K, Asami T, et al. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats. Endocrinology. 2012;153(11):5297–308. pmid:23027808
  41. 41. Tanaka T, Ohkura S, Wakabayashi Y, Kuroiwa T, Nagai K, Endo N, et al. Differential effects of continuous exposure to the investigational metastin/kisspeptin analog TAK-683 on pulsatile and surge mode secretion of luteinizing hormone in ovariectomized goats. J Reprod Dev. 2013;59(6):563–8. pmid:24047956
  42. 42. Yamamura T, Wakabayashi Y, Sakamoto K, Matsui H, Kusaka M, Tanaka T, et al. The effects of chronic subcutaneous administration of an investigational kisspeptin analog, TAK-683, on gonadotropin-releasing hormone pulse generator activity in goats. Neuroendocrinology. 2014;100(2–3):250–64. pmid:25428554
  43. 43. d'Anglemont de Tassigny X, Fagg LA, Carlton MB, Colledge WH. Kisspeptin can stimulate gonadotropin-releasing hormone (GnRH) release by a direct action at GnRH nerve terminals. Endocrinology. 2008;149(8):3926–32. Epub 2008/05/03. pmid:18450966
  44. 44. Uenoyama Y, Inoue N, Pheng V, Homma T, Takase K, Yamada S, et al. Ultrastructural evidence of kisspeptin-gonadotrophin-releasing hormone (GnRH) interaction in the median eminence of female rats: implication of axo-axonal regulation of GnRH release. J Neuroendocrinol. 2011;23(10):863–70. Epub 2011/08/06. pmid:21815953
  45. 45. Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab. 2015;100(9):3322–31. pmid:26192876